First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy

Am J Hematol. 2021 Jun 1;96(6):755-756. doi: 10.1002/ajh.26026. Epub 2020 Nov 6.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antigens, CD / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology*
  • Bone Marrow / virology
  • DNA, Viral / blood
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Doxorubicin / administration & dosage
  • Epstein-Barr Virus Infections / drug therapy
  • Epstein-Barr Virus Infections / etiology*
  • Epstein-Barr Virus Infections / pathology
  • Gemcitabine
  • Humans
  • Immunocompromised Host
  • Lymph Nodes / pathology*
  • Lymph Nodes / virology
  • Lymphoproliferative Disorders / drug therapy
  • Lymphoproliferative Disorders / etiology*
  • Lymphoproliferative Disorders / pathology
  • Male
  • Middle Aged
  • Nitriles
  • PAX5 Transcription Factor / analysis
  • Prednisone / administration & dosage
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / etiology
  • Pyrazoles / adverse effects*
  • Pyrimidines
  • RNA, Viral / analysis
  • Reed-Sternberg Cells / chemistry
  • Reed-Sternberg Cells / pathology*
  • Reed-Sternberg Cells / virology
  • Thrombocythemia, Essential / complications
  • Thrombocythemia, Essential / genetics
  • Vinblastine / administration & dosage

Substances

  • Antigens, CD
  • DNA, Viral
  • Epstein-Barr virus encoded RNA 1
  • Nitriles
  • PAX5 Transcription Factor
  • PAX5 protein, human
  • Pyrazoles
  • Pyrimidines
  • RNA, Viral
  • Deoxycytidine
  • Vinblastine
  • Doxorubicin
  • ruxolitinib
  • Prednisone
  • Gemcitabine